drugset / Trial / NCT06117878
Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma
Phase 0
Unknown
12 enrolled
Base Therapeutics (Shanghai) Co., Ltd.
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of NK510 in the treatment of Osteosarcoma and Soft Tissue Sarcoma.NK510 will be administered by intravenous injection. The safety and efficacy of this treatment will be evaluated.
Timeline
- Start
- 2022-09-01
- Primary completion
- 2024-09-01
- Completion
- 2024-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NK510 | Cell therapy | 1e+09 cells | Intravenous |
| Subject | NK510 | Cell therapy | 3e+09 cells | Intravenous |
| Subject | NK510 | Cell therapy | 9e+09 cells | Intravenous |